Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISER: Repatha in Intracranial Atherosclerosis
NCT04573777Phase 4Terminated
- Sponsor
- University of California, Los Angeles
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of evolocumab in intracranial atherosclerosis (ICAD), sponsored by University of California, Los Angeles. Primary endpoint: Percent Stenosis at 1.5 years. Started Apr 2021; status: terminated.
02
Drugs
evolocumab
03
Conditions
intracranial atherosclerosis (ICAD)
Beyond the preview
Go deeper on NCT04573777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573777.